Condensed Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 30,503	$ 12,562
General and administrative	10,303	2,685
Total operating expenses	40,806	15,247
Loss from operations	(40,806)	(15,247)
Interest income	5,005	105
Interest expense		(1,604)
Net change in fair value of redeemable convertible preferred stock tranche obligations		(58)
Change in fair value of derivative liabilities		6,453
Loss on extinguishment of convertible notes		(2,316)
Other income (expense), net	(10)	(80)
Net loss	(35,811)	(12,747)
Other comprehensive loss:
Unrealized loss on marketable securities	(279)
Comprehensive loss	$ (36,090)	$ (12,747)
Net loss per share attributable to common stockholders, basic	$ (0.87)	$ (21.36)
Net loss per share attributable to common stockholders, diluted	$ (0.87)	$ (21.36)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	40,995,901	596,738
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	40,995,901	596,738